PT  - JOURNAL ARTICLE
AU  - Adam Howes
AU  - Kathryn A. Risher
AU  - Van Kính Nguyen
AU  - Oliver Stevens
AU  - Katherine M. Jia
AU  - Timothy M. Wolock
AU  - Rachel Esra
AU  - Lycias Zembe
AU  - Ian Wanyeki
AU  - Mary Mahy
AU  - Clemens Benedikt
AU  - Seth R. Flaxman
AU  - Jeffrey W. Eaton
TI  - Spatio-temporal estimates of HIV risk group proportions for adolescent girls and young women across 13 priority countries in sub-Saharan Africa
AID  - 10.1101/2022.07.12.22277551
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.12.22277551
4099  - http://medrxiv.org/content/early/2022/07/13/2022.07.12.22277551.short
4100  - http://medrxiv.org/content/early/2022/07/13/2022.07.12.22277551.full
AB  - Background The Global AIDS Strategy 2021-2026 identifies adolescent girls and young women (AGYW) as a priority population for HIV prevention, and recommends differentiated intervention portfolios geographically based on local HIV incidence and individual risk behaviours. We aimed to estimate prevalence of HIV risk behaviours and associated HIV incidence at a small spatial scale among AGYW living in 13 countries in sub-Saharan Africa.Methods We analysed 46 geospatially referenced national household surveys conducted between 1999-2018 across 13 high burden countries in sub-Saharan Africa. Female survey respondents aged 15-29 years were classified into four risk groups (not sexually active, cohabiting, non-regular or multiple partner[s] and female sex workers [FSW]) based on reported sexual behaviour. We used a Bayesian spatio-temporal multinomial regression model to estimate the proportion of AGYW in each risk group stratified by district, year, and five-year age group. Using subnational estimates of HIV prevalence and incidence produced by countries with support from UNAIDS, we estimated new HIV infections in each risk group by district and age group. We then assessed the efficiency of prioritising interventions according to risk group.Results Data consisted of 274,970 female survey respondents aged 15-29. Among women aged 20-29, cohabiting (63.1%) was more common in eastern Africa than non-regular or multiple partner(s) (21.4%), while in southern countries non-regular or multiple partner(s) (58.5%) were more common than cohabiting (23.4%). Risk group proportions varied substantially across age groups (65.9% of total variation explained), countries (20.9%), and between districts within each country (11.3%), but changed little over time (0.9%). Prioritisation based on behavioural risk, in combination with location- and age-based prioritisation, reduced the proportion of population required to be reached in order to find half of all expected new infections from 19.3% to 10.6%. FSW were 1.4% of the population but 10.9% of all expected new infections.Conclusions Our risk group estimates provide data for HIV programmes to set targets and implement differentiated prevention strategies outlined in the Global AIDS Strategy. Successfully implementing this approach would result in more efficiently reaching substantially more of those at risk for infections.Author summary Exposure to HIV among adolescent girls and young women depends on the level of unsuppresed HIV in their local community among potential partners, and their individual sexual behaviour. To support HIV programmes in identifying and providing services to those at highest risk, we geographically mapped HIV risk groups using sexual risk behaviour data from household surveys and estimated the proportion of people living with HIV in each risk group, and the rate of infections in each risk group. Doing so also allowed us to estimate the the proportion of people living with HIV in each risk group, as well as the rate of new infections in each risk group. We found that prioritising HIV prevention using behavioural risk groups almost halved the proportion of the population that would need to be reached to find half of all expected new infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAH was supported by the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning (EP/S023151/1). AH, VKN, KAR, JWE were supported by the Bill and Melinda Gates Foundation (OPP1190661, OPP1164897). TMW was supported by Imperial College London (President's PhD Scholarship). SF was supported by the EPSRC (EP/V002910/2). JWE was supported by UNAIDS and National Institute of Allergy and Infectious Disease of the National Institutes of Health (R01AI136664). LZ, IW, MM and CB are employed by UNAIDS. This research was supported by the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth \& Development Office (FCDO), under the MRC/FCDO Concordat program and is also part of the EDCTP2 programme supported by the European Union.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involved secondary analysis of household survey data which are publicly accessible upon reasonable request from the Demographic and Health Survey (DHS) and Population HIV Impact Assessment (PHIA) websites (https://dhsprogram.com/data/available-datasets.cfm; https://phia-data.icap.columbia.edu/datasets). All DHS were reviewed and approved by ICF International and local Institutional Review Board in the implementing country (https://dhsprogram.com/Methodology/Protecting-the-Privacy-of-DHS-Survey-Respondents.cfm). Ethical approval for PHIA surveys was granted by the Institutional Review Boards of the US Centers for Disease Control and Prevention and Columbia University Irving Medical Center and relevant local IRB in each implementing country. Therefore, this study did not require further ethical approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/athowes/multi-agyw. https://github.com/athowes/multi-agyw